Overview of Opioid Use Disorder

Similar documents
Module II Opioids 101 Opiate Opioid

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

Mark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

2/21/2018. What are Opioids?

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Opioid Use in Youth. Amy Yule M.D. March 2,

Opioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.

Opioids. Sergio Hernandez, MD

Opioid Treatment in North Carolina SEPTEMBER 13, 2016

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA

Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic

Buprenorphine pharmacology

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

Charles P. O Brien, MD, PhD University of Pennsylvania No financial conflicts, patents, speakers bureaus

MAT - ICAAD 2018 Ron Jackson, MSW, LICSW

5/29/2015. Responding to the Opioid Crisis. Responding to the Opioid Crisis. Objectives

Opiate Use Disorder and Opiate Overdose

Medication-Assisted Treatment. What Is It and Why Do We Use It?

ROSC & MAT II: Opioid Treatment Services

Buprenorphine as a Treatment Option for Opioid Use Disorder

Opioids Research to Practice

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs

Addressing Alaska s Opioid Epidemic From Understanding to Action

Opioid Use Issues: All the Players

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

Medication-Assisted Treatment (MAT) Overview

Opioid Overdose Epidemic A Crises and Opportunity

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Building capacity for a CHC response to Ontario's Opioid Crisis

Medication Assisted Treatment. Michael Palladini, RPh MBA CAC

Prescription Opioid Addiction

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

Opioids Research to Practice

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

MAT in the Corrections Setting

Opioid Epidemic Update

Treatment Alternatives for Substance Use Disorders

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

Opioid dependence and buprenorphine treatment

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018

Opioids Research to Practice

The Unseen Consequences of Prescription Drug Abuse. Stephen Loyd, M.D.

MEDICATION ASSISTED TREATMENT

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services

PAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)

Treatment of Opioid Use Disorder

Treatment of Opioid Use Disorder

Identification and Treatment of Opioid Use Disorders in Primary Care Settings

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE

Mayors Opioid Summit PATTERNS AND TRENDS OF THE OPIOID EPIDEMIC IN BROWARD COUNTY TYPES OF OPIOIDS DEFINITION OF OPIOID. Pill Press from China

Tapering Opioids Best Practices*

Treating Opioid Addiction

Understanding and Combating the Heroin Epidemic

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Addressing Opiate Abuse

Heroin, Fentanyl and Other Opioids. Steve Hanson

Acute General Medical and Surgical Admission:

Opioids Research to Practice

Treatment Approaches for Drug Addiction

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare

Strategies to Manage The Opioid Crisis

Optimizing Suboxone in Opioid Addicts

Attitudes Toward Medication-Assisted Treatment Within a Drug Court Program. Caroline Allison. Dr. Kathleen Moore, Ph.D.

Medication Assisted Treatment. Nicole Gastala, MD

What is an opioid? What do opioids do? Why is there an opioid overdose crisis? What is fentanyl? What about illicit or bootleg fentanyls?

Evidence-Based Practices for the Treatment of Opioid Use Disorder. Zach Ludwig, LPC Corporate Director Clinical Programs Bradford Health Services

Opioid Dependence and Buprenorphine Management

Recognizing Narcotic Abuse and Addiction and Helping Those With It

Talking with your doctor

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Appendix F Federation of State Medical Boards

Top 10 narcotic pain pills

Medication for Addiction Treatment (MAT)

Medication-Assisted Treatment (MAT) for Opioid Use Disorders

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.

Preventing Opioid Misuse and Use: The Lucky Preventionist s Guide to Strategic Planning

Opioids and Opioid Addiction: Practical Management Approaches

8/28/2017. Headlines. How Did We Get Here? Pain is the number one reason patients go the doctors office, urgent care and/or emergency room.

MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER

A Prescription for Education. Hillary Dubois, Director of Prevention Services Amanda Sandoval, Asst. Director of Prevention Services

Module Two: Pharmacotherapies for Opioid Substitution Treatment

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford

Opioid dependence: Detoxification

Vivitrol Vs. Suboxone

History of Present Illness (HPI) Assessment and Plan Template

The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country

OPIATES AND ADDICTION MEDICATIONS. Dr. Carroll W. Thornburg, D.O Chief Medical Officer in Primary Care and Addiction Services

2004-L SEPTEMBER

The Rising Tide of Prescription Opioid Use Disorders and Current Treatment Options

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Transcription:

Overview of Opioid Use Disorder Doug Burgess, MD Medical Director of Outpatient Services, Truman Medical Centers Assistant Professor of Psychiatry, University of Missouri- Kansas City

Objectives History and epidemiology of opioid use disorders Why do people become addicted to opiates and why is it difficult to stop Overview of medication assisted treatment of opioid use disorders Questions

TABLE 19-3. Drug relationships for withdrawal Methadone, 1 mg, is equivalent to Codeine, 30 mg Dromoran, 1 mg Fentanyl, 0.01 mg Heroin, 1 2 mg Hydrocodone, 0.5 mg Hydromorphone, 0.5 mg Laudanum (opium tincture), 3 ml Levorphanol, 0.5 mg Meperidine, 20 mg Morphine, 3 4 mg Oxycodone, 1.5 mg Paregoric, 7 8 ml Textbook of Substance Abuse Treatment, 4 th ed. Galanter, M.D., Marc.

Opiate Use - A Brief History 1980s Mass opiophobia leading to reports of pain undertreatment 1898 Heroin synthesized as safer, non-addictive upgrade from morphine, mass distribution 1970 Controlled Substances Act categorized regulated drugs under 5 schedules 2000s JCAHO deems pain fifth vital sign, opioid prescribing further increased dramatic rise in opioid misuse, abuse, ED visits 3400 BC Opium poppy cultivated in Mesopotamia 1800s Morphine isolated from opium, widely used in Civil War 1916 Oxycodone synthesized as safer upgrade from heroin 1990s New extendedrelease opioids, expanded use 2010s abusedeterrent formulations, education and public awareness, drug monitoring programs TIME [http://www.theatlantic.com/sponsored/purdue-health/a-brief-history-of-opioids/184/]

SOURCE: National Institute on Drug Abuse, www.nida.nih.gov.

A Growing Problem Chronic pain is defined as pain beyond the usual aches and pains that lasts for at least 3 months 10 % of all Americans report pain lasting longer than one year (Centers for Disease Control and Prevention, NATIONAL Center for Health Statistics 2006) The use of Chronic Opioid Therapy has increased dramatically over the last 20 years Emphasis on pain control (Now considered a vital sign) Aggressive marketing Decreased time spent with patients Improved treatment outcomes Change in patient expectations Not enough prescriber education

Missouri Prescribing Patterns?

Non-Prescription Use of Opioids In a month, 4.3 million Americans use prescription painkillers nonmedically Last year, 1.9 million Americans met criteria for prescription opioid use disorder Average age of first use 21.2 Despite increase in opioid prescriptions, there has been no overall change in amount of pain reported by Americans.

Age at time of Opioid Abuse/Misuse

Overdose On the Rise The most common drugs involved in OD include Methadone Oxycodone (OxyContin) Hydrocodone (Vicodin) More people died from drug OD in 2014 than any year on record. More than 6/10 involved an opioid. From 1999-2014, 165,000 Americans died from overdoses related to prescription opioids 44-78 Americans die every day from overdose of prescription painkillers

Rates of Hospital Inpatient and ED Visits for Opioid Overuse by Region

60,000 Causes of Death in America 2015 50,000 40,000 30,000 20,000 10,000 0 Drug Overdoses HIV/AIDS Car Crashes Gun Homicides Source: Centers for Disease Control

Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: 2010-2011 Note: The percentages do not add to 100 percent due to rounding. 1 The Other category includes the sources "Wrote Fake Prescription," "Stole from Doctor's Office/Clinic/Hospital/Pharmacy," and "Some Other Way." Source: SAMHSA, 2011 National Survey Drug Use and Health

Heroin Use in the USA - Increasing 580 people initiate heroin use daily 2014 heroin OD deaths >10,500 (quadrupled from 2002) Mortality rate tripled since 2010, more than doubled among 18- to 25-yearolds Among new heroin users, approximately 75% report having abused prescription opioids prior to using heroin

Prescription Street Value - Roughly $1/mg - Large number of purchasers naive to illegal drug market so cost fluctuates So why do people move to heroin? - One study found availability is a large factor

DSM- 5 Criteria for Substance Use Disorder 2 or more of the following: Failure to fulfill obligations at work, home or school Recurrent use in hazardous situations Continued use despite recurrent social or interpersonal problems Tolerance Withdrawal Larger amounts/longer period than intended Persistent desire to cut back/quit Great deal of time using or recovering from use Social, occupational, recreational activities given up Continued use despite knowledge of physical, psychological consequences INTENSE CRAVING

Addictive Behavior = Survival Behavior Gone Awry (Courtesy of Steve LaRowe, PhD) Over the course of evolution, we have developed circuits in our brains that promote our survival. Drugs of addiction activate this survival circuitry to an exaggerated degree, and with chronic use, essentially take it over. In the late stages of addiction, an individual is basically a survivalist doing whatever it takes to acquire and use drugs regardless of the costs. Motivation has changed

Hijacking the Basic Survival Circuitry (Courtesy of Steve LaRowe, PhD)

Survival Circuits (Courtesy of Steve LaRowe, PhD) 1. Reward Circuitry -- LIKING 2. Memory Circuitry 3. Motivation, Drive Salience Circuitry CRAVING/WANTING 3. Orbital-Frontal Cortex 1. VTA 1. Nucleus Accumbens 2. Hippocampus 2. Amygdala

Opioid withdrawal Opioid Withdrawal Flushing Diarrhea Muscle cramps Flu-like sxs Nausea Agitation Hallucinations Stomach cramps Sleep problems Sweating -1 0 1 2 3 4 5 6 7 8 9 STOP DRUG Days

Opioid Withdrawal Syndrome Protracted Symptoms Deep muscle aches and pains Insomnia, disturbed sleep Poor appetite Reduced libido, impotence, anorgasmia Depressed mood, anhedonia Drug craving and obsession

Environment Exposure Physical Illness Cognition Genes Traumatic Experiences Perceived Norms Substance Use Disorder Learned Coping Strategies Positive Effects Withdrawal Mental Illness Support Group Access to Treatment

Treatment of Opioid Use Disorder Prevention Education Patients and the public in general Physicians Monitoring Prescription Monitoring Programs Physician prescribing practices Access to appropriate Treatment for chronic pain Treatment Detoxification Limited efficacy- high relapse rates Treat co-morbid illnesses 12-step and community support groups

Medications for the treatment of withdrawal symptoms Symptom relief Autonomic excitability (jittery,restless)- clonidine Nausea/vomiting- perphenazine, ondansetron Diarrhea- Lomotil, loperamide Muscle cramps- cyclobenzaprine, methacarbamol Pain- NSAIDS Insomnia- trazodone, zolpidem

Medication Assisted Treatment (MAT) of Opioid Use Disorder Pharmacological Methadone: reduces mortality and morbidity, illicit drug use, criminal activity Suboxone (buprenorphine): more accessible, less potential for euphoric effects or overdose Naltrexone: perhaps better for patients with current employment, Sobriety as a contigency

Methadone Long acting opioid with limited euphoric effect Highly structured programs Ability to level up Dosing: 60 120 mg/day Downsides: Limited access and flexibility Highly stigmatized Expensive and time consuming Can be associated with sedation, constipation and potentially dangerous interactions with other medications May be most appropriate for those with more severe opioid use disorders- highly structured treatment

Methadone regulations Regulated by Substance Abuse and Mental Health Services Administration (SAMHSA) and state agency Only provided in opiate treatment programs One year history of dependence and current use 18 and older, if younger must have failed 2 non opiate treatments in the prior 12 months and guardian consent Daily dosing, limited take home if doing well in the program Take home dose increases with successful time in clinic, up to 2 week supply after a year and a maximum of a month supply after 2 years Psychosocial treatments

Buprenorphine/naloxone (Suboxone) Regulation: Drug Addiction Treatment Act, (DATA 2000) allowing qualified physicians to prescribe Schedule III, IV, and V medications for the treatment of opioid addiction. MDs can receive training and obtain special permission from the DEA to prescribe this Makes opiate dependence treatment more accessible Required to refer to substance abuse treatment

Suboxone Partial activation of opioid receptor sites Prevents withdrawal and cravings Ceiling effect makes them safer in terms of overdose Opioids are unable to produce effect/euphoria Suboxone also contains naloxone Opioid receptor blocker Not absorbed sublingually Prevents injection

Partial vs. Full Opioid Agonist death Opiate Effect Full Agonist (e.g., methadone) Partial Agonist (e.g. buprenorphine) Dose of Opiate Antagonist (e.g. Naloxone)

Suboxone Dosing: 8 16 mg/day, ceiling of 24-32mg/day Most common side effects Constipation, sweating Usually not much sedative effect Potentially dangerous in patients with severe liver disease, uncontrolled alcohol use and use of other sedating medications

Buprenorphine/naloxone Three Stages of treatment: Induction: 2-3 day period of observed administration must be in mild to moderate opiate withdrawal Can be done in the hospital or in community setting Stabilization: Meeting weekly to monitor SE and cravings adjust dose to curb cravings and minimize withdrawal Maintenance: achieved sobriety stable dose

Rough Graph of Suboxone Induction 120 100 80 60 40 Opiates Suboxone 20 0 Pre-Treatment Day 1 Day 2 Category 4

Naltrexone How it works: blocks opioids from binding to their receptors No effect from opiates Decreased cravings Patients have to be free from opioids for several days prior to starting this medication Can cause nausea, headaches and rare cases of liver damage. Prescription opiates will not work for pain control Available as a long acting injection (Vivitrol) Useful in individuals whose livelihood is contingent on sobriety

Duration of Treatment Substance use disorders are chronic diseases Genetics, life experiences, coping strategies, long term exposure to substances and other factors all contribute to the development of the condition. Not substituting one drug for another Decision to taper or stop is based on clinical picture and personal choices about treatment Like any other treatment, it is based on analysis of risk v. benefits

What treatment looks like http://www.kansascity.com/news/local/article1 43441464.html

Questions?